Check out your Company Bowl for anonymous work chats.
How do we become smarter in our approach to helping people manage chronic conditions, like type 2 diabetes and hypertension, well before their health is at risk? It starts with data. To shift the care paradigm from one-size-fits-all and provide personalized interventions, we need to understand the many factors that influence a person’s health. Read how our Onduo solution aims to do just that.
Looking for purposeful work that can change the world of health? Verily is hiring across functions, and most roles are remote. We're an Alphabet company and offer Google perks & benefits. Check out open roles today!
"The confluence of multiple different types of data and datasets that we have, coupled with the ability to continuously in a stepwise way, inform and optimize care across time. That is now becoming more and more precision medicine and precision health." -Amy Abernethy, President, Clinical Research Platforms, Verily Dr. Abernethy along with co-panelists Andrea Ramirez, Gaurav Singal, MD, and Lloyd Minor, discuss precision medicine in the era of genomics at the 2022 #FutureofHealthData Summit. You can watch the entire discussion from the Summit, on-demand here: https://bit.ly/3geIuJg
Today STAT covered how Verily is laying the foundation for a future of real-world evidence generation, enabling #PrecisionHealth. What does it mean to build next generation clinical trials? At Verily, we’re building the tools and infrastructure needed to broaden the types of data used in clinical trials and build quality longitudinal data sets to bring more representative data into decisions made about drugs and medical devices. We’re expanding our capabilities with software like eConsent forms to conduct clinical research, clinical trial management systems for physical trial sites, dataset assembly and management, study recruitment, and sensor-based data collection through hardware like its Study Watch. Each capability builds upon each other, making up an end-to-end clinical research suite. #PrecisionHealth #EvidenceGeneration
Verily is hiring across several businesses, with many positions remote. As an Alphabet company, we offer extensive benefits, perks, and competitive compensation. Explore jobs: https://bit.ly/3SYG4wm
In an interview with pharmaphorum, our Head of Molecular Science Charlie Kim spoke about the latest breakthrough in Verily's collaborative research effort with Sosei Heptares, including our human-first precision approach to drug target discovery. "Immune-mediated diseases are highly complex and, oftentimes, therapies that work for one patient may not be effective for another. Precision health seeks to create the greatest number of options possible, as well as make sure every patient has the most targeted treatment for their condition, physiology, and more." – Charlie Kim Read the article for more.
Now is the time to join Verily! "Alphabet's Verily raises $1 bln in funding round"
The Project Baseline Health study just published a new paper in Journal of Affective Disorders that looks at the complex associations between socioeconomic factors and anxiety. The findings show the importance of taking a whole person approach when diagnosing and treating anxiety. Congrats to the authors, contributing teams, and the 2.5K+ study participants on this important effort to advance the field and improve health for all! #SocialDeterminantsOfHealth #SDoH #anxiety
The latest coming out of Verily! Leveraging high-resolution multi-omic data and sophisticated analytics, together with Sosei Heptares we were able to prioritize and advance high-confidence GPCR targets into target validation in just six months. Learn how our Immune Profiler platform’s human-first precision approach to drug discovery can accelerate and enhance drug development.
We are continuing our big moves at Verily. Read about our recent work with Google Health developing an AI to recognize different phases of complex LC surgeries (gallbladder removal). Explore our open roles in this important work to help make surgeries safer for all.
